Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Stem cell transplantation has emerged as a relatively popular treatment that can help to regulate immunity, repair injury, and control inflammation. Several studies have used autologous stem cells or adipose-derived stem cells to treat Crohn's disease and its associated complications, and have achieved good efficacy. Thus far, the use of umbilical cord mesenchymal stem cells (UC-MSCs) to treat Crohn's disease has rarely been reported. In this study, UC-MSCs were used to treat patients with hormone-controlled Crohn's disease. We observed the disease control conditions, corticosteroid dosage changes, and treatment-related adverse reactions.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fuzhou General Hospital
• Collaborator: Shaanxi Provincial People's Hospital
• Treatments: Hormones

Criteria

Inclusion Criteria:

• above 18 years of age

• moderate to severe Crohn's disease (Crohn's disease activity index (CDAI) between 220 and 450)

• had received hormone maintenance therapy for more than 6 months

Exclusion Criteria:

• active tuberculosis

• malignancy

• HIV

• syphilis

• hepatitis B

• hepatitis C